Back to News
Market Impact: 0.2
Arcturus Therapeutics Holdings Consensus Price Target Increased by 14.69% to $22.75
Source: Nasdaq
Analyst EstimatesHealthcare & Biotech
The aggregate one-year analyst price target for Arcturus Therapeutics was raised 14.69% to $22.75 per share from $19.83 on August 25, 2026. The revision signals improved analyst expectations for the biotech company, though the article provides no underlying earnings, clinical, or operational catalyst.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
ARCT0.40
More News
- Arctic Minerals at Aktiedagen 2026: swedish copper push gains pace
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Beta Bionics prices $150M public offering at $17.25/share
- Inside South Korea’s university programs offering a direct route to Samsung and SK Hynix
- DST Global Advisors sells $6.86m in Chime Financial stock
- Why Radiant Logistics Stock Topped the Market on Tuesday
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: AI-Powered Report Editing, Investor Relations, and Enhanced Search
- Automating Financial Model Updates: A Source-Controlled Workflow